Skip to main content
Medy-Tox Inc. logo

Medy-Tox Inc. — Investor Relations & Filings

Ticker · 086900 ISIN · KR7086900008 KO Manufacturing
Open in API
Filings indexed 414 across all filing types
Latest filing 2024-05-16 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 086900

About Medy-Tox Inc.

https://www.medytox.com/?site_id=en

Medy-Tox Inc. is a biopharmaceutical company focused on the research, development, and commercialization of biologic products. Its primary offerings are centered on botulinum toxin type A (BTX-A) formulations, including Neuronox®, INNOTOX®, Coretox®, and NEWLUX®, which are used for both aesthetic and therapeutic applications. The company is noted for developing the world's first liquid-injectable botulinum toxin. In addition to its toxin portfolio, Medy-Tox manufactures and markets a line of hyaluronic acid (HA) dermal fillers, such as Neuramis®, Atiere, and Potenfill. The company's product range also extends to dermocosmetics under the NEURADERM brand.

Recent filings

Filing Released Lang Actions
분기보고서 (2024.03)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Report' (분기보고서) for Medytox Inc. for the period ending March 31, 2024. It contains detailed financial statements, management discussion and analysis, and corporate governance information, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2024
2024-05-16 Korean
연결재무제표기준영업(잠정)실적(공정공시)
Earnings Release Classification · 1% confidence The document is a 'Provisional Earnings Release' (영업(잠정)실적) for Medytox, detailing quarterly financial performance (2024.1Q) including revenue, operating profit, and net income. It is a standard regulatory disclosure of preliminary financial results, which fits the definition of an Earnings Release (ER). Q1 2024
2024-05-10 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details share transactions (purchases) made by a director (Jung Hyun-ho) of Medytox. This is a standard regulatory filing for insider trading/director dealings in the Korean market, which corresponds to the 'Director's Dealing' category.
2024-04-12 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is an official announcement of the results of a General Meeting of Shareholders (AGM). It details the approval of financial statements, dividend resolutions, and other agenda items voted upon during the meeting held on 2024-03-29. This falls under the category of Declaration of Voting Results & Voting Rights Announcements.
2024-03-29 Korean
감사보고서제출
Audit Report / Information Classification · 1% confidence The document is a regulatory filing from Medytox titled 'Audit Report Submission' (감사보고서 제출). It provides a summary of financial statements, audit opinions, and key financial metrics for the current and previous fiscal years. While it contains financial data, it is a standard regulatory disclosure form used in the Korean market to announce the completion and submission of the audit report to the exchange, rather than the full annual report document itself. Therefore, it is classified as a Regulatory Filing (RNS). FY 2023
2024-03-21 Korean
사업보고서 (2023.12)
Annual Report Classification · 1% confidence The document is a '사업보고서' (Business Report) for the fiscal year 2023 (2023.01.01 ~ 2023.12.31) filed by Medytox Inc. to the Financial Supervisory Service and Korea Exchange. It contains comprehensive financial statements, management discussion and analysis, governance information, and operational details. This structure corresponds to the standard Korean Annual Report filing, which is equivalent to the 10-K filing category. FY 2023
2024-03-21 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.